STOCK TITAN

[Form 4] Rhythm Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Rhythm Pharmaceuticals (RYTM) director Edward T. Mathers received new equity compensation grants on June 24, 2025. The awards consist of:

  • Stock Options: 7,037 options with an exercise price of $63.66, exercisable until June 23, 2035
  • Restricted Stock Units (RSUs): 4,712 units, each convertible to one common share

Both grants will fully vest on the earlier of June 24, 2026 or the day before the 2026 annual stockholder meeting, subject to continued service. The options provide the right to purchase shares at the specified strike price, while the RSUs represent a contingent right to receive shares upon vesting with no purchase requirement. This compensation structure aligns the director's interests with long-term shareholder value.

Edward T. Mathers, direttore di Rhythm Pharmaceuticals (RYTM), ha ricevuto nuove assegnazioni di compensi azionari il 24 giugno 2025. Le concessioni includono:

  • Opzioni su azioni: 7.037 opzioni con un prezzo di esercizio di 63,66 $, esercitabili fino al 23 giugno 2035
  • Unità azionarie vincolate (RSU): 4.712 unità, ciascuna convertibile in una azione ordinaria

Entrambe le assegnazioni matureranno completamente alla data anticipata tra il 24 giugno 2026 o il giorno precedente l'assemblea annuale degli azionisti del 2026, subordinatamente al mantenimento del rapporto di servizio. Le opzioni concedono il diritto di acquistare azioni al prezzo stabilito, mentre le RSU rappresentano un diritto condizionato a ricevere azioni al momento della maturazione senza obbligo di acquisto. Questa struttura di compenso allinea gli interessi del direttore con il valore a lungo termine per gli azionisti.

Edward T. Mathers, director de Rhythm Pharmaceuticals (RYTM), recibió nuevas concesiones de compensación en acciones el 24 de junio de 2025. Las adjudicaciones consisten en:

  • Opciones sobre acciones: 7,037 opciones con un precio de ejercicio de $63.66, ejercitables hasta el 23 de junio de 2035
  • Unidades de acciones restringidas (RSU): 4,712 unidades, cada una convertible en una acción común

Ambas concesiones se consolidarán completamente en la fecha que ocurra primero entre el 24 de junio de 2026 o el día anterior a la junta anual de accionistas de 2026, sujeto a la continuidad del servicio. Las opciones otorgan el derecho a comprar acciones al precio especificado, mientras que las RSU representan un derecho contingente a recibir acciones al consolidarse sin necesidad de compra. Esta estructura de compensación alinea los intereses del director con el valor a largo plazo para los accionistas.

Rhythm Pharmaceuticals (RYTM)의 이사 Edward T. Mathers2025년 6월 24일에 새로운 주식 보상 부여를 받았습니다. 부여 내용은 다음과 같습니다:

  • 스톡 옵션: 행사가격 $63.66인 7,037주, 2035년 6월 23일까지 행사 가능
  • 제한 주식 단위(RSU): 각각 보통주 1주로 전환 가능한 4,712 단위

두 부여 모두 2026년 6월 24일 또는 2026년 연례 주주총회 전날 중 빠른 날짜에 전액 베스팅되며, 계속 근무 조건이 적용됩니다. 옵션은 지정된 행사가격으로 주식을 구매할 권리를 제공하고, RSU는 구매 없이 베스팅 시 주식을 받을 수 있는 조건부 권리입니다. 이러한 보상 구조는 이사의 이익을 장기 주주 가치와 일치시키는 역할을 합니다.

Edward T. Mathers, administrateur de Rhythm Pharmaceuticals (RYTM), a reçu de nouvelles attributions d’actions le 24 juin 2025. Les récompenses comprennent :

  • Options d’achat d’actions : 7 037 options avec un prix d’exercice de 63,66 $, exerçables jusqu’au 23 juin 2035
  • Unités d’actions restreintes (RSU) : 4 712 unités, chacune convertible en une action ordinaire

Les deux attributions seront totalement acquises à la date la plus proche entre le 24 juin 2026 ou la veille de l’assemblée générale annuelle des actionnaires de 2026, sous réserve de la poursuite du service. Les options donnent le droit d’acheter des actions au prix fixé, tandis que les RSU représentent un droit conditionnel à recevoir des actions à l’acquisition sans obligation d’achat. Cette structure de rémunération aligne les intérêts de l’administrateur sur la valeur à long terme pour les actionnaires.

Edward T. Mathers, Direktor von Rhythm Pharmaceuticals (RYTM), erhielt am 24. Juni 2025 neue Aktienvergütungszuteilungen. Die Auszeichnungen umfassen:

  • Aktienoptionen: 7.037 Optionen mit einem Ausübungspreis von 63,66 $, ausübbar bis zum 23. Juni 2035
  • Restricted Stock Units (RSUs): 4.712 Einheiten, jeweils umwandelbar in eine Stammaktie

Beide Zuteilungen werden vollständig am früheren der beiden Termine 24. Juni 2026 oder dem Tag vor der Jahreshauptversammlung 2026 fällig, vorbehaltlich fortgesetzter Dienstzeit. Die Optionen gewähren das Recht, Aktien zum festgelegten Ausübungspreis zu erwerben, während die RSUs ein bedingtes Recht darstellen, bei Vesting Aktien ohne Kaufpflicht zu erhalten. Diese Vergütungsstruktur richtet die Interessen des Direktors auf den langfristigen Wert für die Aktionäre aus.

Positive
  • None.
Negative
  • None.

Edward T. Mathers, direttore di Rhythm Pharmaceuticals (RYTM), ha ricevuto nuove assegnazioni di compensi azionari il 24 giugno 2025. Le concessioni includono:

  • Opzioni su azioni: 7.037 opzioni con un prezzo di esercizio di 63,66 $, esercitabili fino al 23 giugno 2035
  • Unità azionarie vincolate (RSU): 4.712 unità, ciascuna convertibile in una azione ordinaria

Entrambe le assegnazioni matureranno completamente alla data anticipata tra il 24 giugno 2026 o il giorno precedente l'assemblea annuale degli azionisti del 2026, subordinatamente al mantenimento del rapporto di servizio. Le opzioni concedono il diritto di acquistare azioni al prezzo stabilito, mentre le RSU rappresentano un diritto condizionato a ricevere azioni al momento della maturazione senza obbligo di acquisto. Questa struttura di compenso allinea gli interessi del direttore con il valore a lungo termine per gli azionisti.

Edward T. Mathers, director de Rhythm Pharmaceuticals (RYTM), recibió nuevas concesiones de compensación en acciones el 24 de junio de 2025. Las adjudicaciones consisten en:

  • Opciones sobre acciones: 7,037 opciones con un precio de ejercicio de $63.66, ejercitables hasta el 23 de junio de 2035
  • Unidades de acciones restringidas (RSU): 4,712 unidades, cada una convertible en una acción común

Ambas concesiones se consolidarán completamente en la fecha que ocurra primero entre el 24 de junio de 2026 o el día anterior a la junta anual de accionistas de 2026, sujeto a la continuidad del servicio. Las opciones otorgan el derecho a comprar acciones al precio especificado, mientras que las RSU representan un derecho contingente a recibir acciones al consolidarse sin necesidad de compra. Esta estructura de compensación alinea los intereses del director con el valor a largo plazo para los accionistas.

Rhythm Pharmaceuticals (RYTM)의 이사 Edward T. Mathers2025년 6월 24일에 새로운 주식 보상 부여를 받았습니다. 부여 내용은 다음과 같습니다:

  • 스톡 옵션: 행사가격 $63.66인 7,037주, 2035년 6월 23일까지 행사 가능
  • 제한 주식 단위(RSU): 각각 보통주 1주로 전환 가능한 4,712 단위

두 부여 모두 2026년 6월 24일 또는 2026년 연례 주주총회 전날 중 빠른 날짜에 전액 베스팅되며, 계속 근무 조건이 적용됩니다. 옵션은 지정된 행사가격으로 주식을 구매할 권리를 제공하고, RSU는 구매 없이 베스팅 시 주식을 받을 수 있는 조건부 권리입니다. 이러한 보상 구조는 이사의 이익을 장기 주주 가치와 일치시키는 역할을 합니다.

Edward T. Mathers, administrateur de Rhythm Pharmaceuticals (RYTM), a reçu de nouvelles attributions d’actions le 24 juin 2025. Les récompenses comprennent :

  • Options d’achat d’actions : 7 037 options avec un prix d’exercice de 63,66 $, exerçables jusqu’au 23 juin 2035
  • Unités d’actions restreintes (RSU) : 4 712 unités, chacune convertible en une action ordinaire

Les deux attributions seront totalement acquises à la date la plus proche entre le 24 juin 2026 ou la veille de l’assemblée générale annuelle des actionnaires de 2026, sous réserve de la poursuite du service. Les options donnent le droit d’acheter des actions au prix fixé, tandis que les RSU représentent un droit conditionnel à recevoir des actions à l’acquisition sans obligation d’achat. Cette structure de rémunération aligne les intérêts de l’administrateur sur la valeur à long terme pour les actionnaires.

Edward T. Mathers, Direktor von Rhythm Pharmaceuticals (RYTM), erhielt am 24. Juni 2025 neue Aktienvergütungszuteilungen. Die Auszeichnungen umfassen:

  • Aktienoptionen: 7.037 Optionen mit einem Ausübungspreis von 63,66 $, ausübbar bis zum 23. Juni 2035
  • Restricted Stock Units (RSUs): 4.712 Einheiten, jeweils umwandelbar in eine Stammaktie

Beide Zuteilungen werden vollständig am früheren der beiden Termine 24. Juni 2026 oder dem Tag vor der Jahreshauptversammlung 2026 fällig, vorbehaltlich fortgesetzter Dienstzeit. Die Optionen gewähren das Recht, Aktien zum festgelegten Ausübungspreis zu erwerben, während die RSUs ein bedingtes Recht darstellen, bei Vesting Aktien ohne Kaufpflicht zu erhalten. Diese Vergütungsstruktur richtet die Interessen des Direktors auf den langfristigen Wert für die Aktionäre aus.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mathers Edward T

(Last) (First) (Middle)
104 5TH AVE
19TH FLOOR

(Street)
NEW YORK NY 10011

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $63.66 06/24/2025 A 7,037 (1) 06/23/2035 Common Stock 7,037 $0 7,037 D
Restricted Stock Units (2) 06/24/2025 A 4,712 (3) (3) Common Stock 4,712 $0 4,712 D
Explanation of Responses:
1. The options fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date.
2. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
3. The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.
/s/ Zachary Bambach, attorney-in-fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did RYTM director Edward Mathers receive in June 2025?

Edward Mathers received 7,037 stock options with an exercise price of $63.66 on June 24, 2025. These options will fully vest on either June 24, 2026, or the day before RYTM's 2026 annual stockholder meeting, whichever comes first.

How many restricted stock units (RSUs) were granted to Edward Mathers by RYTM?

Edward Mathers was granted 4,712 restricted stock units (RSUs) on June 24, 2025. Each RSU represents the right to receive one share of RYTM common stock upon vesting.

When do Edward Mathers' RYTM stock options and RSUs vest?

Both the stock options and RSUs will fully vest upon the earlier of: (i) June 24, 2026, or (ii) the day immediately prior to RYTM's 2026 annual stockholder meeting, subject to Mathers' continued service through the vesting date.

What is the total value of RYTM equity compensation granted to Edward Mathers?

The grant consists of 7,037 stock options with a strike price of $63.66 and 4,712 restricted stock units. Both were granted at $0 cost to Mathers, though the options will require payment of the exercise price to convert to shares.

What position does Edward Mathers hold at RYTM?

Edward Mathers serves as a Director on RYTM's Board of Directors, as indicated by the 'X' marked in the Director box on the Form 4 filing.
Rhythm Pharmaceu

NASDAQ:RYTM

RYTM Rankings

RYTM Latest News

RYTM Latest SEC Filings

RYTM Stock Data

3.94B
59.58M
0.54%
107.82%
8.14%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON